Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.
Proposed changes to this list are open for consultation. Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for ...
the HIV medication Biktarvy and the cancer drug Xtandi. The list price on Merck's diabetes drug Janumet increased 293% since it hit the market in 2007, the largest increase among all 25 drugs ...
That needs to go much beyond this licensing that was already signed. We also have long-acting cabotegravir [a drug used for the treatment of HIV/AIDS], which … has been available for four years now.
It usually happens when someone has AIDS. Drugs that treat HIV and related infections can also trigger rashes. These often go away several days or weeks after you stop taking the drug. Talk with ...